John R. Moore - 12 Aug 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role: General Counsel
Signature: /s/ John R. Moore
Issuer symbol: EWTX
Transactions as of: 12 Aug 2025
Net transactions value: -$28,097
Form type: 4
Filing time: 14 Aug 2025, 19:43:39 UTC
Previous filing: 07 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
MOORE JOHN R	General Counsel	C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER	/s/ John R. Moore	14 Aug 2025	0001191702

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EWTX	Common Stock	Options Exercise	$0	+5,781	+89%	$0.000000	12,312	12 Aug 2025	Direct
transaction	EWTX	Common Stock	Sale	$28,097	-2,098	-17%	$13.39	10,214	12 Aug 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EWTX	Restricted Stock Units	Options Exercise	$0	-5,781	-25%	$0.000000	17,344	12 Aug 2025	Common Stock	5,781	$0.000000	Direct	F3
transaction	EWTX	Restricted Stock Units	Award	$0	+26,875		$0.000000	26,875	12 Aug 2025	Common Stock	26,875	$0.000000	Direct	F4
transaction	EWTX	Stock Option (Right to Buy)	Award	$0	+161,250		$0.000000	161,250	12 Aug 2025	Common Stock	161,250	$13.39	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
F2	The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
F4	Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
F5	1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.